logo-loader
viewBrewin Dolphin

Brewin Dolphin knocked as house broker cuts price target

Liberum lowered to its target to 394p from 481p, even though it was impressed by the 6.8% rise in new money coming in

smartphone
Personal advice is booming at Brewin

Brewin Dolphin PLC (LON:BRW) suffered a share price downgrade by its house broker even though the wealth manager reported another year of strong fund inflows.

Liberum lowered to its target to 394p from 481p, even though it was impressed by the 6.8% rise in new money coming in during the year to September.

READ: Brewin Dolphin posts higher profits as inflows continue

The house also reduced its forecasts in 2019 and 2020 by 3.5% and 2.5% respectively to reflect ‘larger client growth leading to larger clients move up pricing tiers’.

Shore Capital, meanwhile, maintained a price target of 420p and kept Brewin Dolphin as its top pick in the wealth management sub-sector.

One concern, though, said Shore was Brewin's intent to undertake a major IT upgrade of custody ansd settlement service over the next two years, which might “run a mild chill down the spine” of investors.

The last major IT project at Brewin ended with a £34mln write-off being taken in 2014 as the project was abandoned David Nicol when he took over as chief executive.

Brewin shares eased 4% to 320p.

Quick facts: Brewin Dolphin

Price: 347.6 GBX

LSE:BRW
Market: LSE
Market Cap: £1.05 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

8 hours, 55 minutes ago

RNS

Director/PDMR Shareholding

3 days, 10 hours ago

Director/PDMR Shareholding

4 days, 7 hours ago

Director/PDMR Shareholding

1 week, 1 day ago

Total Voting Rights

1 week, 1 day ago

Preliminary Report

1 week, 6 days ago

Total Voting Rights

on 4/11/19

2 min read